Swiss voters reject exec pay limit; GSK planning $40.5M Scotland expansion;

@FiercePharma: The weekend's best-read special report: Top 10 Pharma Companies by 2012 Revenue. Report | Follow @FiercePharma

@EricPFierce: FDA approves, buys GSK vaccine in case of H1N1 pandemic. More | Follow @EricPFierce

@CarlyHFierce: Voters in Switzerland turn down strict CEO pay limits. Story | Follow @CarlyHFierce

> Swiss voters resoundingly rejected a proposal to limit pay for top executives to 12 times that of junior employees--an idea that was opposed by Roche ($RHHBY) CEO Severin Schwan, among others. Story

> GlaxoSmithKline ($GSK) announced plans to invest £25 million (about $40.5 million) to expand in Scotland, where it will equip its Montrose plant to manufacture four of its drugs. Story

> Pfizer Ltd., the Indian unit of Pfizer Inc. ($PFE), will acquire the Indian affiliate of Wyeth, returning 7 Pfizer Ltd. shares for every 10 shares of Wyeth. Story

> A U.S. District Judge dismissed an SEC lawsuit alleging insider trading in shares of Onyx Pharmaceuticals ($ONYX) in July, when it was weighing the Amgen ($AMGN) takeover, citing insufficient evidence. Story

> Generic drugmaker Arrow Pharma, a unit of Actavis ($ACT), plans to halve the packaging work done at its Malta plant, a move that could affect 20 workers. Story

> Indian drug giant Ranbaxy Laboratories is weighing a selloff of Biovel, a Bangalore-based vaccine maker that it acquired in 2010. Story

> Shortly after Germany's Merck KGaA said it would shut down operations at two of its Puerto Rico plants, local mayor Wanda Soler predicted heavy job losses from pharma cutbacks on the island. Story

> An eighth student has been diagnosed with meningitis at Princeton University, which says it will begin innoculating students with Novartis's ($NVS) investigational vaccine in December. Story

> Trevor Mundel, president of global health operations for the Gates Foundation, tells Xconomy he's rethinking how the organization values its investments. Story

Medical Device News

@FierceMedDev: A French start-up nailed some major financing for its retinal implant - a $20M-plus Series A. Story | Follow @FierceMedDev

@MarkHFierce: TB Dx maker Oxford Immunotec launched a relatively-modest IPO but it gained steam in initial trading. Friday's story | Follow @MarkHFierce

> Under Icahn's pressure, Hologic's M&A prospects heat up. Story

> Key piece of Roche, Novo Nordisk diabetes device deal nears EU approval. Article

> Sorin CE nails CE mark for extra-large size of sutureless aortic valve. Item

Biotech News

@FierceBiotech: Welcome Galen Moore, the new managing editor of FierceBiotechFiercePharma and FierceMedicalDevices! | Follow @FierceBiotech

@JohnCFierce: Whoa, FDA gets mighty cross with 23andMe, tackles Anne Wojcicki. Want to see what angry regulators look like? FDA warning letter | Follow @JohnCFierce

@DamianFierce: With $43M in the bank, startup Editas sets off in pioneering "molecular surgery" field. News | Follow @DamianFierce

@EmilyMFierce: Biota scraps preclinical antibiotics program as antimicrobial resistance grows. Story | Follow @EmilyMFierce

> Biotech pioneer in 'gene editing' launches with $43M in VC cash. Story

> Orexigen shares soar as long-delayed weight drug clears PhIII safety hurdle. News

> ARMO emerges from stealth mode, preps study of discarded Merck drug. Article

> Portola shoots for early FDA approval after nabbing 'breakthrough' status. Story

> Cubist surges on positive PhIII antibiotic study. Item

CRO News

> Indian CROs leap into U.S. with joint venture. News

> Pharmacyclics, J&J pick Catalent for blockbuster cancer drug. More

> ResearchDx reaches into India for contract diagnostics work. News

> Covance taps NeoGenomics for cancer trial diagnostics. Article

> Vietnam taps Quintiles to up its stake in global trials. Story

Biotech IT News

> Google begins hiring team to lead Calico. More

> Life sciences IT execs plan business intelligence spending blitz. News

> Lilly, Novartis and Pfizer sign up to improve ClinicalTrials.gov. Story

> Report finds inexcusable failings in government cybersecurity. Piece

> Novartis looks to data management vendors to slash costs. Article

Suggested Articles

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.

FDA advisors will question the clinical data and manufacturing for Mesoblast's Ryoncil, a cell therapy for pediatric acute graft vs. host disease.